Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50904 |
Name | salivary gland carcinoma |
Definition | A salivary gland cancer that has_material_basis_in epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer oral cavity cancer salivary gland cancer salivary gland carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600E | Dabrafenib + Trametinib | salivary gland carcinoma | predicted - sensitive | detail... |
BRAF V600E | Vemurafenib | salivary gland carcinoma | predicted - sensitive | detail... |
HRAS act mut | Tipifarnib | salivary gland carcinoma | sensitive | detail... |
PTEN L152P PTEN neg | AZD8186 | salivary gland carcinoma | resistant | detail... |
PTEN L152P PTEN neg | GSK2636771 | salivary gland carcinoma | resistant | detail... |
PTEN L152P PTEN neg | Alpelisib | salivary gland carcinoma | resistant | detail... |
PTEN L152P PTEN neg | Alpelisib + AZD8186 | salivary gland carcinoma | sensitive | detail... |
PTEN L152P PTEN neg | Pictilisib | salivary gland carcinoma | sensitive | detail... |
FGFR2 Y375C | Lirafugratinib | salivary gland carcinoma | predicted - sensitive | detail... |
HRAS G13V PIK3CA E545K | Tipifarnib | salivary gland carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Unknown status | CAN | 0 |
NCT03146650 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer | Active, not recruiting | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03749460 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | Completed | USA | 0 |
NCT03942653 | Phase II | Goserelin + Pembrolizumab | Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma | Recruiting | USA | 0 |
NCT04832438 | Phase II | Carboplatin + Elraglusib | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | Withdrawn | USA | 0 |
NCT05010629 | Phase II | Carboplatin + Elraglusib | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma | Active, not recruiting | USA | 0 |
NCT05408845 | Phase II | Docetaxel + Trastuzumab Ado-trastuzumab emtansine | Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer | Recruiting | USA | 0 |
NCT05513365 | Phase II | Bicalutamide + Goserelin Bicalutamide + Dutasteride + Goserelin | Phase II Dutasteride in Combination With CAB vs CAB in SDC (DUCT) | Recruiting | NLD | 0 |
NCT05884320 | Phase II | Sacituzumab govitecan-hziy | Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Salivary Gland Cancers | Recruiting | USA | 0 |
NCT06648096 | Phase Ib/II | Afatinib | Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (AFAN) | Not yet recruiting | ESP | DEU | 0 |